

Physicians’ perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices

Jonathan A. Bernstein,¹ Tonya A. Winders,² Jessica McCarthy,³ Pallavi Saraswat,⁴ Nadine Chapman-Rothe,⁵ Tara Raftery,⁶ Karsten Weller⁷

¹Bernstein Allergy Group and Clinical Research Center, Cincinnati, OH, USA; ²Global Allergy and Airways Patient Platform, Vienna, Austria; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ⁴Novartis Healthcare Pvt. Ltd., Hyderabad, India; ⁵Novartis Pharma AG, Basel, Switzerland; ⁶Novartis Ireland Ltd., Dublin, Ireland; ⁷Institute of Allergology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt – Universität zu Berlin, Berlin, Germany

INTRODUCTION

- Chronic spontaneous urticaria (CSU) is characterised by the occurrence of itch, hives and/or angioedema for more than 6 weeks and can have a major impact on patients’ well-being¹
- Previously published pooled data from the Urticaria Voices study indicated a significant unmet need amongst physicians and increase awareness of the impact of CSU on patients²

OBJECTIVE

- This analysis from the Urticaria Voices study investigated country-wide physicians’ perspective on the burden of CSU for patients, unmet needs of physicians and their treatment goals

METHODS

Study Design

- Urticaria Voices is a global (United States of America, Canada, United Kingdom, Germany, France, Italy and Japan) cross-sectional online survey conducted in patients with CSU and CSU-treating physicians
- Physicians (dermatologists and allergists or immunologists) who treat patients with CSU completed a 30-min online survey between February 2022 and August 2022 and rated their responses either on a 10-point scale or as percentage scores


Study Assessments and Data Analysis

- Physicians’ perspective on all analysed parameters was recorded as percentage scores
- Measures of CSU burden on patients and treatment goals for patients with CSU were collected on a 10-point scale, with 1 denoting the lowest score and 10 denoting the highest score. Top 3 box results refer to the percentage of physicians choosing a high score of 8, 9 or 10
- Data were analysed using descriptive statistics and reported as percentage

RESULTS

- A total of 862 physicians (dermatologists, n=517; allergists, n=345) participated in the study. More than half of the physicians perceived CSU as a serious disease, and approximately 65% felt that it negatively impacts patients’ lives
- Physicians reported high scores (mean±standard deviation) for perceived negative impact on patients’ mental well-being (8.2±1.7), social life and intimate relationships (7.8±1.7), activities of daily living (7.5±1.8), professional lives (7.5±1.8), family life (7.4±1.9) and ability to reach full life potential (6.1±2.0)
- Notably, while the high disease burden is recognised by physicians across countries, the extent of perception varies for all categories (**Figure 1**)
- Physicians considered improvement in overall quality of life (81%), being free from itch and hives (75%), improved sleep (74%) and ability to perform daily activities (73%) as the most important treatment goals for patients with CSU
- However, the extent of physicians’ perception varied between countries, e.g. ranging from 90% of physicians in Canada to 70% in Japan, perceived improvement in overall quality of life as a treatment goal (top 3 box scores of high importance; **Figure 2**)

Figure 1. Percentage of physicians, per country, ranking high levels of importance to disease burden categories in CSU



- Physicians reported several unmet needs, including better understanding of the cause of CSU (48%), better access to treatments (47%), reduced administrative barriers for prescribing biologics (45%) and increased awareness of disease among primary care practitioners (44%) and public (37%)
- The extent of physicians’ perception also differed for all categories of unmet needs, for instance, 80% of physicians in Canada versus 25% in France requested for better access to treatments (**Figure 3**)

Figure 2. Percentage of physicians, per country, ranking high levels of importance to treatment goal categories in CSU





Figure 3. Percentage of physicians, per country, ranking high levels of importance to unmet need categories in CSU



References

- Zuberbier T, et al. *Allergy*. 2022;77(3):734–766.
- Winders TA, et al. Poster presentation at: *ECAAI* 2024; 31 May–3 June 2024; Valencia, Spain. Abstract 000401.

Acknowledgements

The authors thank all patients and physicians who participated in the study. All authors participated in the development of the poster for presentation. The authors thank Pedro A. Laires (former employee of Novartis Pharma AG, Basel, Switzerland) for his contribution to the study and Mihai Dricu (Ipsos SA, Basel, Switzerland) for statistical analysis. The authors thank Sagar Wagh and Suparna Mukherjee for writing assistance and Moganti Ravi Sankar for design support (all from Novartis Healthcare Pvt. Ltd., Hyderabad, India), which was funded by Novartis Pharma AG, Basel, Switzerland, in accordance with the Good Publication Practice (GPP2022) guidelines (<https://www.ismpp.org/gpp-2022>).

Disclosures

Jonathan A. Bernstein reports grants from Novartis, AstraZeneca, Sanofi-Regeneron, Amgen, Roche, Allakos, Celldex, CSL Behring, Takeda/Shire, BioCryst, Pharming, Ionis, BioMarin and Genentech outside the submitted work and personal fees from Novartis, AstraZeneca, Sanofi-Regeneron, Amgen, Roche, Allakos, Celldex, CSL Behring, Takeda/Shire, BioCryst, Pharming, Ionis, BioMarin and Genentech outside the submitted work. **Tonya Winders** receives funds from unbranded disease awareness and education from Novartis, AstraZeneca, Sanofi-Regeneron, Amgen, Roche and Genentech outside the submitted work and was an employee of the Allergy and Asthma Network at the time of study conduct. **Jessica McCarthy** is an employee of Novartis Pharmaceuticals Corporation, East Hanover, USA. **Pallavi Saraswat** is an employee of Novartis Healthcare Pvt. Ltd., Hyderabad, India. **Nadine Chapman-Rothe** is an employee of Novartis Pharma AG, Basel, Switzerland. **Tara Raftery** is an employee of Novartis Ireland Ltd., Dublin, Ireland. **Karsten Weller** reports grants from Novartis and Takeda outside the submitted work and personal fees from BioCryst, BioMarin, CSL Behring, Novartis, Moxie and Takeda outside the submitted work.



Scan to obtain:
• Poster

To download a copy of this poster, visit the web at: <https://bit.ly/P3624>
Copies of this poster obtained through quick response (QR) code are for personal use only and may not be reproduced without written permission of the authors.